09:56 AM EST - Numinus Wellness Inc. : Has formally submitted the clinical trial application to Health Canada for its Phase 1 study, HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01. This milestone further progresses and solidifies Numinus' long-standing work on developing safe and effective psychedelic products out of its Health Canada-licensed research facility, Numinus Bioscience. Numinus Wellness Inc.
shares T.NUMI are trading up $0.01 at $0.71.
